Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Review

NF-κB as potential target in the treatment of melanoma

Authors: Gabriele Madonna, Claudio Dansky Ullman, Giusy Gentilcore, Giuseppe Palmieri, Paolo Antonio Ascierto

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.
Appendix
Available only for authorised users
Literature
1.
Oliveria S, Dusza S, Berwick M: Issues in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2001, 1: 453-459. 10.1586/14737140.1.3.453.CrossRefPubMed
2.
Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM: Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II. J Clin Oncol. 2008, 26: 527-534. 10.1200/JCO.2007.12.7837.CrossRefPubMed
3.
Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA: Main roads to melanoma. J Transl Med. 2009, 86: 1-17.
4.
Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V: Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006, 12: 2301-2307. 10.1158/1078-0432.CCR-05-2518.CrossRef
5.
Kol JM, Fisher DE: A new era: melanoma genetics and therapeutics. J Pathol. 2011, 223: 241-250.
6.
Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009, 27: 2823-30. 10.1200/JCO.2007.15.7636.CrossRefPubMed
7.
McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008, 26: 2178-85. 10.1200/JCO.2007.14.8288.CrossRefPubMed
8.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364: 2507-16. 10.1056/NEJMoa1103782.CrossRefPubMedPubMedCentral
9.
Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. ASCO Annual Meeting. 2008
10.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-23. 10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral
11.
Ascierto PA, Streicher HZ, Sznol M: Melanoma: a model for testing new agents in combination therapies. J Transl Med. 2010, 8: 38-10.1186/1479-5876-8-38.CrossRefPubMedPubMedCentral
12.
Kashani-Sabet M, Shaikh L, Miller JR, Nosrati M, Ferreira CMM, Debs RJ, Sagebiel RW: NF-{kappa}B in the Vascular Progression of Melanoma. J Clin Oncol. 2004, 22: 617-623. 10.1200/JCO.2004.06.047.CrossRefPubMed
13.
Kashani-Sabet M, Liu Y, Fong S, Desprez PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Liggitt D, Thor AD, Debs RJ: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA. 2002, 99 (6): 3878-3883. 10.1073/pnas.002025599.CrossRefPubMedPubMedCentral
14.
Tian B, Brasier AR: Identification of a nuclear factor κ B-dependent gene network. Recent Prog Horm Res. 2003, 58: 95-130. 10.1210/rp.58.1.95.CrossRefPubMed
15.
Ghosh S, Karin M: Missing pieces in the NF-κB puzzle. Cell. 2002, 109: S81-S96. 10.1016/S0092-8674(02)00703-1.CrossRefPubMed
16.
Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-κB activity. Ann Rev Immunol. 2000, 18: 621-663. 10.1146/annurev.immunol.18.1.621.CrossRef
17.
Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000, 12: 85-9. 10.1006/smim.2000.0210.CrossRefPubMed
18.
Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001, 293: 1495-1499. 10.1126/science.1062677.CrossRefPubMed
19.
McNulty SE, Del Rosario R, Cen D, Meyskens FL, Yang S: Comparative expression of NFKB proteins in melanocytes of normal skin vs benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004, 17: 173-80. 10.1111/j.1600-0749.2004.00128.x.CrossRefPubMed
20.
Shattuck-Brandt RL, Richmond A: Enhanced Degradation of I-κBα Contributes to Endogenous Activation of NF-κB in Hs294T Melanoma Cells. Cancer Res. 1997, 57: 3032-PubMed
21.
Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G: Osteopontin Expression Correlates with Melanoma Invasion. J Investig Dermatol. 2005, 124: 1044-1052. 10.1111/j.0022-202X.2005.23680.x.CrossRefPubMed
22.
Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC: Osteopontin: It's Role in Regulation of Cell Motility and Nuclear Factor kB-mediated Urokinase Type Plasminogen activator Expression. IUBMB Life. 2005, 57 (6): 441-447. 10.1080/15216540500159424.CrossRefPubMed
23.
Liu J: Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY: Oncogenic BRAF regulates β-Trcp expression and NF-κB activity in human melanoma cells. Oncogene. 2007, 26 (13): 1954-1958. 10.1038/sj.onc.1209994.CrossRefPubMedPubMedCentral
24.
Dhawan P, Richmond A: A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem. 2002, 277: 7920-8. 10.1074/jbc.M112210200.CrossRefPubMedPubMedCentral
25.
Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 2001, 107: 241-246. 10.1172/JCI11991.CrossRefPubMedPubMedCentral
26.
Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004, 4: 349-60. 10.1038/nrc1361.CrossRefPubMed
27.
Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A: Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 2004, 64: 4912-4918. 10.1158/0008-5472.CAN-04-0673.CrossRefPubMed
28.
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA: A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res. 2010, 16: 348-57. 10.1158/1078-0432.CCR-09-2087.CrossRefPubMedPubMedCentral
29.
Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C: A Study of Paclitaxel, Carboplatin, and Bortezomib in the Treatment of Metastatic Malignant Melanoma. Cancer. 2010, 116: 3463-8. 10.1002/cncr.25191.CrossRefPubMed
30.
Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23: 363-398.PubMed
31.
Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol. 2008, 76: 1340-1351. 10.1016/j.bcp.2008.07.031.CrossRefPubMed
32.
Bill MA, Bakan C, Benson DM, Fuchs J, Young G, Lesinski GB: Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Cancer Res. 2009, 8: 2726-35.
33.
Odot J, Albert P, Carlier A, Tarpin M, Devy J, Madoulet C: In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer. 2004, 111: 381-387. 10.1002/ijc.20160.CrossRefPubMed
34.
Banerji A, Chakrabarti J, Mitra A, Chatterjee A: Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett. 2004, 211: 235-242. 10.1016/j.canlet.2004.02.007.CrossRefPubMed
35.
Pisano M, Pagnan G, Dettori MA, Cossu S, Caffa I, Sassu I, Emionite L, Fabbri D, Cilli M, Pastorino F, Palmieri G, Delogu G, Ponzoni M, Rozzo C: Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol Cancer. 2010, 9: 137-10.1186/1476-4598-9-137.CrossRefPubMedPubMedCentral
36.
Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006, 6: 10-10.1186/1472-6882-6-10.CrossRefPubMedPubMedCentral
37.
Epelbaum R, Schaffer R, Vizel B, Badmaev V, Bar-Sela G: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 2010, 62: 1137-41. 10.1080/01635581.2010.513802.CrossRefPubMed
38.
Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC: BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem. 2003, 278: 1450-6. 10.1074/jbc.M209677200.CrossRefPubMed
39.
Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A: BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways. Clin Cancer Res. 2006, 12: 950-960. 10.1158/1078-0432.CCR-05-1220.CrossRefPubMedPubMedCentral
40.
May MJ, D'Acquisto F, Medge LA, Gluckner J, Pober JS, Ghosh S: Selective inhibition of NFκB activation by a peptide that blocks the interaction of NEMO with the IκB-kinase complex. Science. 2000, 289: 1550-4. 10.1126/science.289.5484.1550.CrossRefPubMed
41.
May MJ, Marienfeld RB, Ghosh S: Characterization of the IκB-kinase NEMO binding domain. J Biol Chem. 2002, 277: 45992-46000. 10.1074/jbc.M206494200.CrossRefPubMed
42.
Di Meglio P, Ianaro A, Ghosh S: Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis and Rheumatism. 2005, 52: 951-958. 10.1002/art.20960.CrossRefPubMed
43.
Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, Sini M, De Maio A, Ombra M, Gentilcore G, Capone M, Ascierto M, Satriano RA, Farina B, Faraone-Mennella M, Ascierto PA, Ialenti A: NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett. 2009, 274: 331-336. 10.1016/j.canlet.2008.09.038.CrossRefPubMed
Metadata
Title
NF-κB as potential target in the treatment of melanoma
Authors
Gabriele Madonna
Claudio Dansky Ullman
Giusy Gentilcore
Giuseppe Palmieri
Paolo Antonio Ascierto
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-53

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue

Research

Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa

Research

Effects of sildenafil and/or muscle derived stem cells on myocardial infarction

Review

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients

Research

Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection

Research

Ca2+-regulatory proteins in cardiomyocytes from the right ventricle in children with congenital heart disease

Methodology

The Stanford Data Miner: a novel approach for integrating and exploring heterogeneous immunological data
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits